|
|
|
|
|
Legal status
Patent not validated
| (51) | INT.CL. | A61K 38/26 | (2006.01) |
| A61K 38/26 | (2013.01) | ||
| A61P 3/10 | (2006.01) | ||
| A61P 9/10 | (2018.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 3/10 | (2018.01) |
| (11) | Number of the document | 3448416 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17721109.1 |
| Date of filing the European patent application | 2017-04-28 | |
| (97) | Date of publication of the European application | 2019-03-06 |
| (45) | Date of publication and mention of the grant of the patent | 2022-08-10 |
| (46) | Date of publication of the claims translation |
| (86) | Number | PCT/EP2017/060160 |
| Date | 2017-04-28 |
| (87) | Number | WO 2017/186896 |
| Date | 2017-11-02 |
| (30) | Number | Date | Country code |
| 16167458 | 2016-04-28 | EP | |
| 16188262 | 2016-09-12 | EP |
| (72) |
HANSEN, Oluf Kristian Højbjerg , DK
|
| (73) |
Novo Nordisk A/S ,
Novo Allé, 2880 Bagsværd,
DK
|
| (54) | SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS |
| SEMAGLUTIDE IN CARDIOVASCULAR CONDITIONS |